Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Long-term safety of alipogene tiparvovec evaluated in patients with lipoprotein lipase deficiency

Sep. 12, 2011

Spherix combination treatment reduces VLDL and LDL in preclinical study

Sep. 9, 2011

Repros Therapeutics presents phase II data on low-dose Proellex

Sep. 9, 2011

Ardea Biosciences provides update on lesinurad development

Sep. 9, 2011

Takeda advances DPP IV inhibitor into Japanese phase III trials in type 2 diabetes

Sep. 8, 2011

TWi Biotechnology completes enrollment in phase IIb AC-201 trial

Sep. 8, 2011

Long-term therapy with cysteamine eye drops assessed in subjects with cystinosis

Sep. 8, 2011

University of Pennsylvania awards grant to OPKO for MPS I therapy

Sep. 7, 2011

Shionogi & Co. claims new neuropeptide Y5 receptor antagonists

Sep. 6, 2011

New progesterone receptor antagonists claimed

Sep. 6, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...